In the phase 2 IMPROVE-HCM trial, cardiac mitotrope ninerafaxstat was safe, with a signal of improved cardiac function in moderate nonobstructive hypertrophic cardiomyopathy.
Philips announced the main terms of an agreement it reached in January with the U.S. government on its new sleep apnea machines, which has already cost the company over 360.
Philips said on Thursday it has reached a settlement to resolve one category of legal claims against it following a major recall of its sleep apnea and respiratory devices.
Market Study Report provides a detailed overview of Medical Ventilator market with respect to the pivotal drivers influencing the revenue graph of this business sphere. The current trends of Medical Ventilator market in conjunction with the geographical landscape, demand spectrum, remuneration scale, and growth graph of this vertical have also been included in this report.